Frontier Scientific, a world leader in porphyrin chemistry and chemical building blocks for drug discovery and material science research, announced their collaboration with Renibus Therapuetics to develop a therapeutic for Covid-19.
US-based biopharmaceutical company Gilead Sciences has agreed to acquire 49.9% equity stake in Pionyr Immunotherapeutics for $275m.
After transferring the media slurry into the open column, the piston is quickly mounted in a way that avoids air entry, and the column is sealed.
Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers. Access to these promising therapies is limited by the high costs of manufacturing at centralized locations. Saint-Gobain Life Sciences, Kanyr Pharma Inc., the RI-MUHC and McGill University have formed a new interdisciplinary consortium to make this technology more accessible. In this project, dendritic cell cancer vaccines will be generated in Saint-Gobain’s VueLife® “C” Series FEP bags.
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology.
Takeda Pharmaceutical has entered into a more than $2bn worth deal with Neurocrine Biosciences to develop potential therapies for psychiatric disorders.
For the outstanding efficiency and scalability, high-performance liquid chromatography (HPLC) has been widely used for purification of high-quality APIs and intermediates in the pharmaceutical industry.
The new pureO3 Dissolved Ozone Sensor with Intelligent Sensor Management (ISM®) technology provides robust, reliable measurement with increased stability in pure water applications.
Financing co-led by ARCH Venture Partners and Cowen Healthcare Investments
IGY Life Sciences has entered into a collaboration with MMS Holdings, a data-focused clinical research organisation (CRO), to advance the development of its anti-CoV-2 therapeutic antibody IgY-110.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.